Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Inclusion Criteria: * Women and men ≥18 years of age * Body weight ≥50 kg. * Confirmed diagnosis of B cellNon-Hodgkin Lymphoma(according to World Health Organization \[WHO\] classification)including Chronic Lymphocytic Leukemia/Small cell Lymphocytic Leukemia (International Workshop),or Waldenstrom's Macroglobulinemia(Second International Workshop) * Have failed ≥1 previous treatment for B-NHL/CLL/WM, and have relapsed or refractory disease following last prior treatment. * Eastern Cooperative Oncology Group performance status of ≤ 2 and a life expectancy of at least 3 months. * Ability to swallow oral capsules without difficulty * Has recovered from adverse toxic effects of prior therapies * Meet the following clinical laboratory requirements: * Creatinine ≤ 1.5 × upper limit of normal (ULN) * Total bilirubin ≤ 1.5 x ULN * AST and ALT ≤ 3 × ULN * Platelet count ≥ 50,000/µL (non-hodgkin \& Waldenstrom's) * Platelet count ≥ 30,000/µL (chronic lymphocytic leukemia) * Absolute Neutrophil count ≥ 1000/µL Exclusion Criteria: * Prior allogeneic bone marrow transplant * Autologous stem cell transplant within 3 months of screening * Active central nervous system involvement * Subjects with autoimmune hemolytic anemia or immune thrombocytopenia * Prior treatment with a Btk inhibitor * Active uncontrolled infection * History of malabsorption * Uncontrolled illness, i.e cardiac, endocrine, respiratory, etc. * History of myocardial infarction, acute coronary syndromes, coronary angioplasty and/or stenting with in the previous 6 months * History of another currently active cancer * History of major surgery within 4 weeks or minor surgery within 1 week * Other medical or psychiatric illness or organ dysfunction * HIV positive * Positive for Hepatitis B surface antigen or Hepatitis C-virus